Impact of therapy with alpha-lipoic acid (ALA) on the oxidative stress in the controlled NIDDM: a possible preventive way against the organ dysfunction? Adjunctive &agr;-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: a double-blind randomized placebo-controlled study Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial. The effect of alpha-lipoic acid (ALA) supplementation on cardiovascular risk factors in men with chronic spinal cord injury: a clinical trial Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Burning mouth syndrome (BMS): an open trial of comparative efficacy of alpha-lipoic acid (thioctic acid) with other therapies. Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alpha-lipoic acid: a randomized double-blinded placebo-controlled study. Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety Effects of Alpha Lipoic Acid on Multiple Cytokines and Biomarkers and Recurrence of Atrial Fibrillation Within 1 Year of Catheter Ablation. α-Lipoic acid treatment of aged type 2 diabetes mellitus complicated with acute cerebral infarction. Effect of alpha-lipoic acid on blood glucose, insulin resistance and glutathione peroxidase of type 2 diabetic patients. Effects of alpha lipoic acid supplementation on serum levels of IL-8 and TNF-α in patient with ESRD undergoing hemodialysis Alpha lipoic acid in burning mouth syndrome--a randomized double-blind placebo-controlled trial. Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Lipoic Acid Prevents High-Fat Diet-Induced Hepatic Steatosis in Goto Kakizaki Rats by Reducing Oxidative Stress Through Nrf2 Activation Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial.
There is a growing evidence that excess generation of highly reactive free radicals , largely due to hyperglycemia , causes oxidative stress , which further exacerbates the development and progression of diabetes and its complications . The purpose of this study was to evaluate the impact of ALA on lipid profile , oxidative pattern and inflammation in patients with controlled non-insulin dependent diabetes mellitus ( NIDDM ) .  ALA , 400mg/day was investigated in NIDDM patients over a period of 4 weeks using a r and omized , placebo-(PLA)-controlled study with two parallel groups . The marker of oxidative stress was the concentration of reactive oxygen metabolites , evaluated using a commercially available test , called d-ROMs  test  , and the  biological antioxidant potential ( BAP ) ; besides , the lipid profile ( total cholesterol = TC , high-density lipoprotein-cholesterol = HDL-C ; low-density lipoprotein-cholesterol = LDL-C , and triglycerides = TG ) and the C-reactive protein ( CRP ) , marker of inflammation were measured at the beginning and at the end of the treatment . A total of 14 patients were r and omly assigned to the two groups . ALA was safe and well tolerated in the only oral daily administration . The d-ROMs test ( p=0.03 ) and HDL-C ( p=0.04 ) showed a significant difference between the two groups . BAP ( p=0.06 ) tended to be higher in the treated patients , while LDL-C ( p=0.07 ) presented a moderate decline . There were no significant differences in TC ( p=0.65 ) , TG ( p=0.78 ) and CRP ( p=0.96 ) between the ALA and PLA groups . ALA therapy appears to reduce significantly d-ROMs and to improve HDL-C value , especially in men with metabolic syndrome treated with oral hypoglycemic drugs . These findings will be useful in patient selection in future clinical trials with ALA in long term studies & agr;-Lipoic acid ( ALA ) has been reported to be effective in reducing body weight in rodents and obese patients . Our previous open trial showed that ALA may play a role in reducing weight gain in patients with schizophrenia on atypical antipsychotics . The present study evaluated the efficacy of ALA in reducing weight and BMI in patients with schizophrenia who had experienced significant weight gain since taking atypical antipsychotics . In a 12-week , double-blind r and omized placebo-controlled study , 22 overweight and clinical ly stable patients with schizophrenia were r and omly assigned to receive ALA or placebo . ALA was administered at 600–1800 mg , as tolerated . Weight , BMI , abdomen fat area measured by computed tomography , and metabolic values were determined . Adverse effects were also assessed to examine safety . Overall , 15 patients completed 12 weeks of treatment . There was significant weight loss and decreased visceral fat levels in the ALA group compared with the placebo group . There were no instances of psychopathologic aggravation or severe ALA-associated adverse effects . ALA was effective in reducing weight and abdominal obesity in patients with schizophrenia who had experienced significant weight gain since beginning an atypical antipsychotic regimen . Moreover , ALA was well tolerated throughout this study . ALA might play an important role as an adjunctive treatment in decreasing obesity in patients who take atypical antipsychotics AIMS We aim ed to analyze the impact of baseline factors on the efficacy of α-lipoic acid ( ALA ) over 4 years in the NATHAN 1 trial . METHODS This was a post-hoc analysis of the NATHAN 1 trial , a 4-year r and omized study including 460 diabetic patients with mild-to-moderate polyneuropathy using ALA 600 mg qd or placebo .  Amongst others , efficacy measures were the Neuropathy Impairment Score of the lower limbs ( NIS-LL ) and heart rate during deep breathing ( HRDB ) . RESULTS Improvement and prevention of progression of NIS-LL ( ΔNIS-LL≥2 points ) with ALA vs. placebo after 4 years was predicted by higher age , lower BMI , male sex , normal blood pressure , history of cardiovascular disease ( CVD ) , insulin treatment , longer duration of diabetes and neuropathy , and higher neuropathy stage . Participants treated with ALA who received ACE inhibitors showed a better outcome in HRDB after 4 years . CONCLUSIONS Better outcome in neuropathic impairments following 4-year treatment with α-lipoic acid was predicted by normal BMI and blood pressure and higher burden due to CVD , diabetes , and neuropathy , while improvement in cardiac autonomic function was predicted by ACE inhibitor treatment . Thus , optimal control of CVD risk factors could contribute to improved efficacy of α-lipoic acid in patients with higher disease burden Study design : A r and omized , double-blind , placebo-controlled clinical trial . Objective : To assess the effect of alpha-lipoic acid ( ALA ) supplementation on IL-6 , hs-CRP , FBS , anthropometric indices , food intake and blood pressure in male patients with chronic spinal cord injury ( SCI ) . Setting : Imam Khomeini Hospital , Tehran University of Medical Sciences , Tehran , Iran . Methods : Fifty-eight men with chronic SCI participated in the study . Participants were divided in two groups : one group received 600 mg of supplemental ALA ( n=28 ) and the other group received placebo ( n=30 ) for 12 weeks . At the beginning and end of the study , biochemical parameters , anthropometric indices , blood pressure and dietary intakes were measured . Dietary intake was measured using N4 software , and statistical analyses were carried out using SPSS16 . Results : No significant reduction was found in IL-6 ( P=0.97 ) and hs-CRP levels ( P=0.23 ) . There was significant reduction in fasting blood sugar ( P=0.001 ) , body weight ( P=0.001 ) , BMI ( P=0.001 ) , waist circumference ( P=0.001 ) and blood pressure ( P=0.001 ) . Dietary intake was significantly reduced , including fat ( P=0.001 ) , carbohydrate ( P=0.001 ) , protein ( P=0.002 ) and energy intakes ( P=0.001 ) . Conclusion : Lipoic acid supplementation had no significant effect on the measured inflammatory markers but it reduces fasting blood sugar , anthropometric parameters , food intake and blood pressure in men with chronic SCI Alpha-lipoic acid ( ALA ) , a naturally occuring compound and a radical scavenger was shown to enhance glucose transport and utilization in different experimental and animal models . Clinical studies described an increase of insulin sensitivity after acute and short-term ( 10 d ) parenteral administration of ALA . The effects of a 4-week oral treatment with alpha-lipoic acid were evaluated in a placebo-controlled , multicenter pilot study to determine see whether oral treatment also improves insulin sensitivity . Seventy-four patients with type-2 diabetes were r and omized to either placebo ( n = 19 ) ; or active treatment in various doses of 600 mg once daily ( n = 19 ) , twice daily ( 1200 mg ; n = 18 ) , or thrice daily ( 1800 mg ; n = 18 ) alpha-lipoic acid . An isoglycemic glucose-clamp was done on days 0 ( pre ) and 29 ( post ) . In this explorative study , analysis was done according to the number of subjects showing an improvement of insulin sensitivity after treatment . Furthermore , the effects of active vs. placebo treatment on insulin sensitivity was compared . All four groups were comparable and had a similar degree of hyperglycemia and insulin sensitivity at baseline . When compared to placebo , significantly more subjects had an increase in insulin-stimulated glucose disposal ( MCR ) after ALA treatment in each group . As there was no dose effect seen in the three different alpha-lipoic acid groups , all subjects receiving ALA were combined in the " active " group and then compared to placebo . This revealed significantly different changes in MCR after treatment ( + 27 % vs. placebo ; p < .01 ) . This placebo-controlled explorative study confirms previous observations of an increase of insulin sensitivity in type-2 diabetes after acute and chronic intravenous administration of ALA . The results suggest that oral administration of alpha-lipoic acid can improve insulin sensitivity in patients with type-2 diabetes . The encouraging findings of this pilot trial need to be substantiated by further investigations BACKGROUND Alpha-lipoic acid ( ALA ) is a potent antioxidant mitochondrial coenzyme , trometamol salt of thioctic acid , shown in clinical studies to be neuroprotective and in a preliminary study to have an effect on the symptomatology of  Burning Mouth Syndrome ( BMS ) .  METHODS We were interested in extending our studies as to whether alpha-lipoic acid might improve the symptomatology in BMS and therefore carried out a larger open controlled clinical study on the effects of alpha-lipoic acid on BMS symptomatology . RESULTS We have examined the effects on 4 groups of 20 patients with BMS of ALA  , compared with bethanecol , Biotene and placebo , and found ALA of remarkable benefit with minimal adverse effects . CONCLUSIONS These results suggest that double-blind r and omized controlled multicenter studies of ALA are indicated Despite well-controlled blood glucose levels , diabetic complications still inevitably take place via several mechanisms including excessive generation of free radicals in patients who suffer from diabetes mellitus ( DM ) . A r and omized double-blind placebo-controlled clinical trial to investigate the effectiveness of oral supplementation of DL-alpha-lipoic acid ( ALA ) on glycemic and oxidative status in DM patients was conducted . Thirty eight out patients with type 2 DM were recruited and r and omly assigned to either placebo or treatment in various doses of ALA ( 300 , 600 , 900 , and 1200 mg/day ) for 6 months . Following the treatment , all subjects were evaluated for glucose status and oxidative biomarkers . Results showed that fasting blood glucose , HbA1c trended to decrease in a dose-dependent manner . Increase of urinary PGF2α-Isoprostanes ( F2α-IsoP ) was noted in placebo but not ALA-treated groups , indicating possible suppressing action of ALA on lipid peroxidation in DM subjects . 8-Hydroxy-2'-deoxyguanosine ( 8-OHdG ) levels , however , were similar in both placebo and ALA groups as well as urinary microalbumin and serum creatinine . Safety evaluation was monitored and treatment was found to be well tolerated despite some minor side effects . Results from this study reflected the benefits of ALA in glucose status with slight efficiency on oxidative stress-related deterioration in DM patients Background Multiple Sclerosis ( MS ) is an inflammatory and demyelinating disease of the central nervous system . Oxidative stress plays a major role in the onset and progression of MS . Asymmetric dimethylarginine ( ADMA ) formation is dependent on oxidative stress status . Objective We examined whether alpha-lipoic acid ( ALA ) as a potent antioxidant could improve the Exp and ed Disability Status Scale ( EDSS ) and decrease plasma level of ADMA in multiple sclerosis patients . Methods In a r and omized , double-blinded clinical trial conducted at Sina Hospital in Tehran , Iran , from September 2009 to July 2011 , 24 patients with relapsing-remitting MS were divided into a treatment group receiving ALA ( 1200mg/day ) for 12 weeks and a control group receiving placebo . Then patients ’ EDSS and Plasma levels of ADMA were measured at baseline and 12 weeks later . Statistical analysis was done by SPSS software version 16 using the K-S test , Chi square , Mann – Whitney U-test and Wilcoxon test . Results The plasma levels of ADMA in the intervention group were decreased significantly ( p=0.04 ) . Also , no patient had increased EDSS score in the supplement group , where 2 out of 12 patients in the placebo group experienced so . Comparing the serum level of ADMA between the two groups failed to show any significant change in the supplement group compared with the control group . Conclusion Considering that ADMA is produced by oxidative stress in MS patients and leads to increase of inflammation , ALA may have the potential of beneficial effects in them , in part , by decreasing the plasma level of ADMA and stopping progression . Trial registration The trial was registered at the Iranian Registry of Clinical Trials ( http://www.i rct .ir ) with the I rct ID : No. I RCT 138812222602N2 . Funding The authors received no financial support for the research , authors hip , and /or publication of this article Background and purpose Nonalcoholic fatty liver disease ( NAFLD ) is one of the causes of a fatty liver , occurring when fat is deposited ( steatosis ) in the liver not due to excessive alcohol use . It is related to insulin resistance and the metabolic syndrome . The purpose of the present study was to evaluate the impact of combination therapy with alpha-lipoic acid ( ALA ) and ursodeoxycholic acid ( UDCA ) on NAFLD . Methods Alpha-lipoic acid 400 mg/day plus UDCA 300 mg/day ( ALAUDCA ) was investigated in patients over a period of 12 months using a r and omized , placebo (PLA)-controlled study with four parallel groups . Serum concentration of gamma-glutamyl transpeptidase ( GGT ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , albumin and platelets ( PLT ) were measured at the beginning and at the end of the treatment . Moreover , the AST/ALT ratio and the NAFLD fibrosis score were examined . Results A total of 120 patients were r and omly assigned to the four groups . ALA and UDCA were safe and well tolerated in the oral daily administration only . AST , ALT , GGT ( p < 0.001 ) showed a significant difference between ALAUDCA and other three groups . Besides , NAFLD fibrosis score underlined a significant reduction ( p < 0.04 ) in the ALAUDCA group , while AST/ALT ratio presented a moderate decline ( p > 0.05 ) . Conclusion ALAUDCA therapy reduced AST , ALT , GGT values and improved NAFLD fibrosis score and AST/ALT ratio , especially in patients who were on a hypocaloric diet . These findings will be useful in patient selection in future clinical trials with ALAUDCA in long-term studies Catheter ablation ( CA ) is a procedure commonly used to restore sinus rhythm in patients with atrial fibrillation ( AF ) . However , AF recurrence after CA remains a relevant clinical issue . We tested the effects of an oral antioxidant treatment ( alpha lipoic acid [ ALA ] ) on AF recurrence post-CA . Patients with paroxysmal AF have been enrolled in a r and omized , prospect i ve , double-blind , controlled placebo trial . After CA , patients have been r and omly assigned to receive ALA oral supplementation ( ALA group ) or placebo ( control group ) and evaluated at baseline and after a 12-month follow-up : 73 patients completed the 12-month follow-up  ( ALA : 33 and control : 40 ) . No significant difference has been detected between the 2 groups at baseline . Strikingly , 1 year after CA , ALA therapy significantly reduced serum markers of inflammation . However , there was no significant difference in AF recurrence events at follow-up comparing ALA with placebo group . Multivariate analysis revealed that the only independent prognostic risk factor for AF recurrence after CA is age . In conclusion , ALA therapy reduces serum levels of common markers of inflammation in ablated patients . Nevertheless , ALA does not prevent AF recurrence after an ablative treatment OBJECTIVE This study aims to evaluate the efficacy and safety of α-lipoic acid in the treatment of aged type 2 diabetes mellitus ( T2DM ) complicated with acute cerebral infa rct ion . PATIENTS AND METHODS 90 patients were r and omly divided into two groups , on the basis of conventional treatment . The experiment group was administrated with α-lipoic acid , while only Vitamin C for the control group , for 3 consecutive weeks . Before and after the experiment , superoxide dismutase ( SOD ) , glutathione peroxidase ( GSH-Px ) and malondialdehyde ( MDA ) levels were measured and scored with the NIHSS ( National Institutes of Health Stroke Scale ) , and the changes of blood glucose , insulin function and other indicators were observed . RESULTS After the treatment , the plasma SOD and GSH-Px levels increased , while MDA decreased ( p < 0.05 ) , with statistical significance when compared with the control group ( p < 0.01 ) . NIHSS score , blood glucose , blood lipids and HOMA-IA of the experiment group decreased significantly ( p < 0.01 ) ; and no significant adverse reactions were found in both groups . CONCLUSIONS α-lipoic acid was safe and effective in the treatment of aged T2DM complicated with acute cerebral infa rct ion , significantly reducing the patient 's oxidative stress , blood glucose and lipid levels and being able to improve islet function OBJECTIVE To examine the effects of alpha-lipoic acid ( ALA ) treatment over a period of 2 months on fasting blood glucose ( FBG ) , insulin resistance ( IR ) , and glutathione peroxidase ( GH-Px ) activity in type 2 diabetes ( T2DM ) patients . METHODS This study took place in Motahari Clinic , Shiraz , Iran , which is affiliated to Shiraz University of Medical Sciences from May to October 2006 . Type 2 DM patients ( n=57 ) were divided into 2 groups to receive either ALA ( 300 mg daily ) or placebo by systematic r and omization , and were followed-up for 8 weeks . After an overnight fasting and 2 hours after breakfast , patients ' blood sample s were drawn and tested for FBG , 2 hours  PPG , serum insulin level , and GH-Px activity .  RESULTS The result of the study showed a significant decrease in FBG and PPG levels , IR-Homeostasis Model Assessment ( IR-HOMA index ) and GH-Px level in the ALA group . The comparison of differences between FBG and IR at the beginning and at the end of study in the ALA treated group and the placebo group were also significant . CONCLUSION This study supports the use of ALA as an antioxidant in the care of diabetic patients Background Chronic renal failure is a progressive and irreversible loss of kidney function , and the hemodialysis ( HD ) is one of the most common modalities in this regard . Oxidative stresses [ like interleukin-8 ( IL-8 ) and tumor necrosis factor-alpha ( TNF-α ) ] and inflammation are the main risk factors associated with cardiovascular diseases and other complications in many organs in hemodialysis patients ; meanwhile , antioxidants like alpha lipoic acid ( ALA ) may reduce the oxidative stress markers and the levels of inflammatory cytokines , so can improve of the patient ’s quality of life . Methods In this r and omized clinical trial study , 60 HD patients were r and omly categorized in two case and control groups . Case group received a daily capsule of 600 mg of ALA supplementation for 8 weeks , and the control group received placebo capsules daily . The serum level of IL-8 and TNF-α was measured in both groups before and after the intervention . Results There were no significant differences in age , gender , duration of dialysis , and causative factor for dialysis between both groups ( P > 0.05 ) . The mean of IL-8 and TNF-α after the intervention in case group was 26.20 ± 15.34 and 21.25 ± 9.61 , respectively ; the difference between both groups was not statistically significant ( P > 0.05 ) . Conclusion Based on the better feeling and other beneficial effects of ALA were found in our study ; we can conclude that it is a beneficial and recommended supplement , especially , for diabetic and dialysis patients UNLABELLED The burning mouth syndrome ( BMS ) is a chronic condition characterized by oral burning pain in the absence of clinical abnormalities and without established therapy . OBJECTIVES The purpose of this study was to evaluate the effectiveness of alpha lipoic acid ( ALA ) in the management of BMS symptoms through a r and omized double-blind placebo-controlled trial . METHODS Thirty-eight patients ( 34 women and four men , median age 62.9 years , range 36 - 78 ) were included and 31 completed the study . The patients were r and omized into two cycles of treatment : one with alpha lipoic acid and one with placebo both administered in identical capsules . These cycles were separated by a washout period of 20 days . The oral symptoms and the treatment response were assessed using a 100-mm visual analog scale before and after each cycle and the global perceived effect score , using a 5-point scale after each treatment cycle . RESULTS The level of reduction on burning was significant for both treatments ( paired t-test : P < 0.05 ; rp = 0.011 ; ral < 0.001 ) . Considering the two cycles together , 22 patients reported at least some improvement after ALA use and 23 patients after placebo . CONCLUSIONS Comparison of the oral assessment scores of the two cycles failed to demonstrate the effectiveness of ALA over placebo ( t-test : P > 0.05 ; r = 0.75 ) OBJECTIVE To evaluate effects of supplementation with alpha-lipoic acid ( ALA ) on the spermatogram and seminal oxidative stress biomarkers . DESIGN R and omized , triple-blind , placebo-controlled clinical trial . SETTING Infertility clinic . PATIENT(S ) Infertile men . INTERVENTION(S ) ALA ( 600 mg ) or placebo for 12 weeks . MAIN OUTCOME MEASURE(S ) Semen analysis , anthropometric , dietary , and physical activity assessment s , total antioxidant capacity , and malondialdehyde . RESULT ( S ) At the end of study , the total sperm count , sperm concentration , and motility in the intervention group were significantly higher than in the control group . In the ALA group , the total sperm count , sperm concentration , and motility levels were also significantly increased at the end of study compared with baseline values . However , there were no significant differences in ejaculate volume , normal morphology percentage , and live sperm between groups . ALA supplementation also result ed in a significant improvement in seminal levels of total antioxidant capacity ( TAC ) and malondialdehyde compared with the placebo . CONCLUSION ( S ) According to the results , medical therapy of asthenoteratospermia with ALA supplement could improve quality of semen parameters . However , further investigation is suggested in this regard . CLINICAL TRIAL REGISTRATION NUMBER I RCT 2013111010181N3 Prevention of hepatic fat accumulation may be an important approach for liver diseases due to the increased relevance of hepatic steatosis in this field . This study was conducted to investigate the effects of the antioxidant α-lipoic acid ( α-LA ) on hepatic steatosis , hepatocellular function , and oxidative stress in a model of type 2 diabetes fed with a high fat diet ( HFD ) . Goto-Kakizaki rats were r and omly divided into four groups . The first group received only a st and ard rat diet ( control GK )  including groups 2 ( HFD ) , 3 ( vehicle group ) , and 4 ( α-LA group ) , which were given HFD , ad libitum during three months . Wistar rats are the non-diabetic control group . Carbohydrate and lipid metabolism , liver function , plasma and liver tissue malondialdehyde ( MDA ) , liver GSH , tumor necrosis factor-α ( TNF-α ) and nuclear factor E2 ( erythroid-derived 2)-related factor-2 ( Nrf2 ) levels were assessed in the different groups . Liver function was assessed using quantitative hepatobiliary scintigraphy , serum aspartate , and alanine aminotransferases ( AST , ALT ) , alkaline phosphatase , gamma-glutamyltranspeptidase , and bilirubin levels . Histopathologically steatosis and fibrosis were evaluated . Type 2 diabetic animals fed with HFD showed a marked hepatic steatosis and a diminished hepatic extraction fraction and both were fully prevented with α-LA  . Plasma and liver tissue MDA and hepatic TNF-α levels were significantly higher in the HFD group when compared with the control group and significantly lower in the α-LA  group . Systemic and hepatic cholesterol , triglycerides , and serum uric acid levels were higher in hyperlipidemic GK rats and fully prevented with α-LA . In addition , nuclear Nrf2 activity was significantly diminished in GK rats and significantly augmented after α-LA treatment . In conclusion , α-LA strikingly ameliorates steatosis in this animal model of diabetes fed with HFD by decrementing the inflammatory marker TNF-α and reducing oxidative stress . α-LA might be considered a useful therapeutic tool to prevent hepatic steatosis by incrementing antioxidant defense systems through Nrf2 and consequently decreasing oxidative stress and inflammation in type 2 diabetes OBJECTIVE The aim of this study was to investigate the effect of alpha-lipoic acid ( ALA ) treatment on endothelium-dependent and -independent vasodilatation , assessed by forearm blood flow ( FBF ) , in patients with type 2 diabetes mellitus . RESEARCH DESIGN AND METHODS A total of 30 subjects with type 2 diabetes were included in this r and omized , controlled , double-blinded , parallel group study . FBF responses to intra-arterial acetylcholine ( ACh ) and glycerol trinitrate ( GTN ) were measured before and after 21 days of intravenous treatment with 600 mg alpha-lipoic acid or placebo . RESULTS FBF responses were comparable at baseline . After treatment , FBF reactivity to ACh and GTN was unchanged in subjects receiving placebo . By contrast , ALA treatment increased endothelium-dependent vasodilatation to ACh ( P < 0.05 ) but not to GTN compared with baseline . CONCLUSIONS Intravenous ALA treatment improves endothelium-dependent vasodilatation in patients with type 2 diabetes , in the absence of effects on forearm vasomotor function . If this salutary action translates into vascular risk reduction remains to be established
Overall , the current meta- analysis demonstrated that ALA administration may lead to an improvement in glucose homeostasis parameters and lipid profiles except HDL-cholesterol levels
OBJECTIVE This systematic review and meta- analysis of r and omized controlled trials ( RCTs ) was performed to summarize the effect of alpha-lipoic acid ( ALA ) supplementation on glycemic control and lipid profiles among patients with metabolic diseases .